Oncimmune Regulatory News (ONC)

14 January 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune to host Science Day at the Royal Institution

on Wednesday 23 January 2019

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, will be hosting a science day for analysts and investors at the Royal Institution, 21 Albemarle Street, London, on Wednesday 23rd January 2019. The event will commence at 3pm GMT followed by a reception at 5.30pm GMT.

The afternoon will feature presentations from Dr. Adam Hill, Chief Executive of Oncimmune; Professor Peter Johnson, Director of the Southampton Cancer Research UK Centre; Professor Tariq Sethi, Vice President AstraZeneca RIA TMU and Emeritus Professor of Respiratory Medicine Kings College London; Professor Frank Sullivan, Professor of Primary Care Medicine at the University of St. Andrews; Dr. Cheung To, Co-founder and Chairman of Gene Group Co. Ltd.; and Dr. Andrea Murray Chief Operational Scientist of Oncimmune. In addition, Oncimmune's Board of Directors and members of its newly formed Scientific Board will be in attendance.

Discussion topics will include stratified cancer care based on tumour characteristics and the tumour micro environment focusing on the role of autoantibodies; opportunities for collaboration and partnerships between Chinese and UK companies arising out of the China Precision Medicine Initiative and the experiences of two companies forging a successful partnership; delayed presentation of cancers in primary care and the Early Detection of Cancer of the Lung, Scotland (ECLS) trial which will report in April 2019.

Agenda

15:00 Welcome by Meinhard Schmidt, Chairman

15:10 Introduction by Dr. Adam Hill, CEO

15:30 Immunology of Cancer - Professor Peter Johnson

15:50 Stratified Medicine and Cancer Care - Professor Tariq Sethi

16:10 Cancer Detection in Primary Care - Professor Frank Sullivan

16:30 The Opportunity in China - Dr. Cheung To & Dr. Andrea Murray

16:50 Thanks - Dr. Adam Hill, CEO

17:00 Q&A

17:30 Networking drinks and canapes

For further information, or to register for the event, please contact Consilium Strategic Communications on oncimmune@consilium-comms.com or +44 (0) 203 709 5700.

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

contact@oncimmune.co.uk

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5700

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT®-Lung and EarlyCDT®-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT®-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit www.oncimmune.com